Last reviewed · How we verify
Ketamine Injectable Solution
At a glance
| Generic name | Ketamine Injectable Solution |
|---|---|
| Also known as | Ketamine |
| Sponsor | The Ketamine Research Foundation |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Pain Reduction for Limb Injuries in Pediatric Emergency Departments: Intranasal Fentanyl or Intranasal Ketamine vs Oral Morphine (PHASE3)
- Anhedonia, Development, and Emotions: Phenotyping and Therapeutics (PHASE4)
- Optimal Timing of Ketamine Initiation for SCD Pain (PHASE3)
- Dexmedetomidine vs Ketamine as Adjuvants to Bupivacaine in Transversus Abdominus Plane Block in Inguinal Hernioplasty (PHASE3)
- Esketamine-propofol Versus Propofol for Flexible Bronchoscopy (PHASE4)
- The Efface of Lidocaine vs. Magnesium Sulphate in the Management of Pain After Laparoscopic Cholecystectomy (PHASE1)
- The Efface of Ketamine vs. Lidocaine in the Management of Pain After Laparoscopic Cholecystectomy (PHASE1)
- The Efface of Ketamine vs. Magnesium Sulphate in the Management of Pain After Laparoscopic Cholecystectomy (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ketamine Injectable Solution CI brief — competitive landscape report
- Ketamine Injectable Solution updates RSS · CI watch RSS
- The Ketamine Research Foundation portfolio CI